Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ATNM

0.00

Stephens & Co. analyst Sudan Loganathan reiterates Actinium Pharma (AMEX: ATNM) with a Overweight and maintains $5 price target.